Decision Resources, Inc., forecasts that Eli Lilly's new serotonin norepinephrine reuptake inhibitor , duloxetine, will be the most promising drug to be launched between 2001-201. Drug Week via NewsEdge Corporation : Decision Resources, Inc., forecasts that Eli Lilly's new serotonin norepinephrine reuptake inhibitor (SNRI), duloxetine, will be the most promising drug to be launched between 2001-201. Duloxetine posses a mechanism of action similar to that of venlafaxine, a popular SNRI already on the market. "Although both Wyeth's venlafaxine and Lilly's duloxetine will share approximately 20% of the depression market in 2011, duloxetine will be favored over venlafaxine because it is not as likely as venlafaxine to cause high blood pressure," said Anathea Waitekus, analyst at Decision Resources. She concluded: "Duloxetine's favorable safety profile will be especially appealing to general practitioners and primary care physicians, who treat the majority of depression sufferers worldwide." This article was prepared by Drug Week editors from staff and other reports. <> << Copyright ©2002 NewsRx.com >>
VII Российский конгресс с международным участием «Молекулярные основы клинической медицины – возможное и реальное» пройдет в Санкт-Петербурге 16 декабря, 2024
Ведущий научный сотрудник НЦПЗ Ирина Федоровна Рощина награждена медалью Г.И. Челпанова 10 декабря, 2024
